Published in Am Heart J on September 16, 2014
Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype. Circulation (2016) 1.47
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet (2016) 0.81
Expert and Advocacy Group Consensus Findings on the Horizon of Public Health Genetic Testing. Healthcare (Basel) (2016) 0.75
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol (2016) 0.75
Familial Hypercholesterolemia: A Systematic Review of Guidelines on Genetic Testing and Patient Management. Front Public Health (2017) 0.75
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Discovery and refinement of loci associated with lipid levels. Nat Genet (2013) 7.86
Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics (2011) 7.30
Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet (1969) 5.13
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet (1990) 3.40
Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation (1974) 3.29
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (2008) 2.62
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ (2002) 2.55
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet (2001) 2.45
Familial hypercholesterolaemia: summary of NICE guidance. BMJ (2008) 2.18
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis (2004) 1.78
Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab (2012) 1.70
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol (2004) 1.61
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.58
Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis (2012) 1.58
Implementation of lipid screening guidelines in children by primary pediatric providers. J Pediatr (2013) 1.47
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol (2011) 1.43
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J (2014) 1.26
Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart (2011) 1.15
Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics (2010) 1.10
Utah's Family High Risk Program: bridging the gap between genomics and public health. Prev Chronic Dis (2005) 1.08
Cascade Screening for Familial Hypercholesterolemia (FH). PLoS Curr (2011) 0.98
Vital signs: avoidable deaths from heart disease, stroke, and hypertensive disease - United States, 2001-2010. MMWR Morb Mortal Wkly Rep (2013) 0.97
Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med (2004) 0.95
Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief (2013) 0.94
Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med (2004) 0.86
Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem (2008) 0.86
Identification of people with heterozygous familial hypercholesterolemia. Curr Opin Lipidol (2012) 0.84
A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol (2013) 0.83
[Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy]. Rev Esp Cardiol (2008) 0.78
Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia. J Clin Lipidol (2009) 0.77
Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J (2013) 0.95
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2014) 0.87
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J (2014) 0.85
Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. Am Heart J (2015) 0.77
Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®). J Am Heart Assoc (2017) 0.75
Untangling the paradox: Obesity as prognostic marker in prevalent cardiovascular disease. Am Heart J (2015) 0.75
Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. Diabetes Care (2016) 0.75